Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study - Ye, Hua; Liu, Shengyun; Xu, Jian; Chai, Kexia; He, Dongyi; Fang, Yongfei; Xie, Qibing; Liu, Huaxiang; Liu, Ying; Hua, Bingzhu; Hu, Jiankang; Zhang, Zhiyi; et al. (Rheumatology and therapy., 2023)
Keywords: Biosimilar; Clinical equivalence; CMAB008; Confidence intervals; Double-blind studies; Family Medicine; General Practice; Immunomodulators; Infliximab; Internal Medicine; Medicine; Medicine & Public Health; Monoclonal antibodies; NCT; NCT03478111; Original Research; Orthopedics; Pharmacokinetics; Quality of Life Research; Rheumatoid arthritis; Rheumatology; Infliximab; CMAB008; Rheumatoid arthritis; Biosimilar; Clinical equivalence